On February 5, 2024, Stacy Coen, SVP & CHIEF BUSINESS OFFICER of Immunogen Inc, executed a sale of 4,583 shares of the company. The transaction was filed with the SEC and is publicly accessible through the SEC Filing. The shares were sold at a price of $29.3 per share, which resulted in a total transaction amount of $134,281.9.
Immunogen Inc, traded under the ticker IMGN, is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancer. The company's proprietary technology allows for the creation of ADCs with a potent cytotoxic payload that can specifically target and kill cancer cells.
Over the past year, the insider, Stacy Coen, has sold a total of 301,809 shares of Immunogen Inc and has not made any purchases of the stock. The insider's recent sale on February 5 is part of a series of transactions over the last twelve months.
The insider transaction history for Immunogen Inc indicates a trend of insider sales, with 20 insider sells and no insider buys over the past year.
As of the date of the insider's recent sale, Immunogen Inc's shares were trading at $29.3, giving the company a market capitalization of $8.243 billion.
The stock's price-to-GF-Value ratio stands at 1.83, with a GF Value of $15.97. This valuation suggests that Immunogen Inc is significantly overvalued according to GuruFocus's proprietary valuation model.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This recent insider sale may provide investors with information about executive sentiment towards the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
